Tech Company Financing Transactions

Rakuten Medical Funding Round

Rakuten Medical closed a $100 million Series F funding round on 1/7/2026. Investors included TaiAx Life Science Fund.

Transaction Overview

Company Name
Rakuten Medical
Announced On
1/7/2026
Transaction Type
Debt
Venture Equity
Amount
$100,000,000
Round
Series F
Investors

TaiAx Life Science Fund

Proceeds Purpose
The company intends to use the funds to advance its top priority: securing U.S. regulatory approval for ASP-1929.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
900 Concar Dr.
San Mateo, CA 94402
USA
Phone
Undisclosed
Website
www.rakuten-med.com
Email Address
Not Recorded
Overview
Rakuten Medical, Inc. is a global biotechnology company developing precision, cell-targeting investigational therapies on its Illuminox technology platform which, in pre-clinical studies have been shown to induce rapid and selective cell killing and tumor necrosis. Illuminox therapies have not yet been approved as safe or effective by any regulatory authority.
Profile
Rakuten Medical LinkedIn Company Profile
Social Media
Rakuten Medical Company Twitter Account
Company News
Rakuten Medical News
Facebook
Rakuten Medical on Facebook
YouTube
Rakuten Medical on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Mickey Mikitani
  Mickey Mikitani LinkedIn Profile  Mickey Mikitani Twitter Account  Mickey Mikitani News  Mickey Mikitani on Facebook
Chief Operating Officer
Brenton Keath
  Brenton Keath LinkedIn Profile  Brenton Keath Twitter Account  Brenton Keath News  Brenton Keath on Facebook
Chief Scientific Officer
Miguel Garcia-Guzman
  Miguel Garcia-Guzman LinkedIn Profile  Miguel Garcia-Guzman Twitter Account  Miguel Garcia-Guzman News  Miguel Garcia-Guzman on Facebook
Chief Technical Officer
Carlos Garcia
  Carlos Garcia LinkedIn Profile  Carlos Garcia Twitter Account  Carlos Garcia News  Carlos Garcia on Facebook
President
Takashi Toraishi
  Takashi Toraishi LinkedIn Profile  Takashi Toraishi Twitter Account  Takashi Toraishi News  Takashi Toraishi on Facebook
Vice President
Jeffrey Berry
  Jeffrey Berry LinkedIn Profile  Jeffrey Berry Twitter Account  Jeffrey Berry News  Jeffrey Berry on Facebook
VP - Bus. Development
Abhijit Bhatia
  Abhijit Bhatia LinkedIn Profile  Abhijit Bhatia Twitter Account  Abhijit Bhatia News  Abhijit Bhatia on Facebook
VP - Bus. Development
Tomasz Zastawny
  Tomasz Zastawny LinkedIn Profile  Tomasz Zastawny Twitter Account  Tomasz Zastawny News  Tomasz Zastawny on Facebook
VP - Finance
Agatha Martindale
  Agatha Martindale LinkedIn Profile  Agatha Martindale Twitter Account  Agatha Martindale News  Agatha Martindale on Facebook
VP - General Counsel
Annie Mcguire
  Annie Mcguire LinkedIn Profile  Annie Mcguire Twitter Account  Annie Mcguire News  Annie Mcguire on Facebook
VP - Human Resources
Suzane San
  Suzane San LinkedIn Profile  Suzane San Twitter Account  Suzane San News  Suzane San on Facebook
VP - Regulatory Affairs
Doreen Gousset
  Doreen Gousset LinkedIn Profile  Doreen Gousset Twitter Account  Doreen Gousset News  Doreen Gousset on Facebook
VP - Regulatory Affairs
Shawn Schaffer
  Shawn Schaffer LinkedIn Profile  Shawn Schaffer Twitter Account  Shawn Schaffer News  Shawn Schaffer on Facebook

 

 

Browse more venture capital transactions:

Prev: 1/7/2026: Sibros venture capital transaction
Next: 1/7/2026: Semafor venture capital transaction

 

Share this article

 

Where The Data Comes From

We report on every notable VC transaction. VC transactions on this site come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2026. Gaebler Ventures. All rights reserved.